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Histone deacetylase inhibitors (HDACi) have become a promising new avenue for cancer therapy, and many are currently in
Phase I/II clinical trials for various tumor types. In the present study, we show that apoptosis induction and histone alterations by
PCI-24781, a novel hydroxamic acid-based HDAC inhibitor, require caspase-8 and the adaptor molecule, Fas-associated death
domain (FADD), in acute leukemia cells. PCI-24781 treatment also causes an increase in superoxide levels, which has been
reported for other HDACi. However, an antioxidant does not reverse histone alterations caused by PCI-24781, indicating that
ROS generation is likely downstream of the eﬀects that PCI-24781 exerts on histone H3. Taken together, these results provide
insight into the mechanism of apoptosis induction by PCI-24781 in leukemia by highlighting the roles of caspase-8, FADD and
increased superoxide levels.
1.Introduction
Epigenetics is currently deﬁned as the heritable changes
in gene expression without alterations in DNA sequence
[1]. Epigenetic alterations include histone modiﬁcation,
DNA methylation, and microRNA expression. In particular,
abnormal histone tail modiﬁcations such as acetylation have
been linked to tumor progression [2]. Histone acetylation is
modulated by two families of enzymes: histone deacetylases
(HDACs) and histone acetyltransferase (HATs). Irregular
patterns of histone acetylation have been hypothesized to
silence tumor suppressor genes in human cancer cells [3].
Consequently, restoring the normal complement of gene
expression has become a therapeutic goal. The HDAC
inhibitors (HDACi) are a structurally diverse family of anti-
cancer drugs that target these abnormal histone acetylations
by inhibiting HDAC enzymes [4]. In mammalian systems,
eleven HDAC enzymes are grouped into four classes based
on structural and functional characteristics. Consequently,
the HDACi compounds are often categorized based on
their ability to inhibit various HDAC classes. The approval
of vorinostat (suberoylanilide hydroxamic acid (SAHA)), a
pan-HDAC inhibitor, by the U.S. Food and Drug Admin-
istration for treatment of cutaneous T-cell lymphoma [5]
was a recent major milestone in validating the clinical utility
of this class of compounds. This success has encouraged
the preclinical and clinical developments of dozens of other
HDACi.2 International Journal of Cell Biology
One such compound is PCI-24781 (formerly known as
CRA-024781), a novel, orally dosed HDACi. Like vorinostat,
PCI-24781 is a hydroxamic acid, and can inhibit all Class
I and Class II HDAC isoforms, although it is reported to
be a more potent inhibitor of HDACs 1 and 3 at low
concentrations [6]. Assessment of in vitro activity against
tumor cell lines revealed growth inhibition of multiple solid
tumor lines including colon, breast, lung, prostate, ovarian,
Hodgkins lymphoma, and non-Hodgkins lymphoma [7].
Only one published study has probed the mechanism of
cell death induced by PCI-24781 in a series of lymphoma
lines and reported caspase activation and generation of
reactive oxygen species, consistent with the mechanism of
cytoxicity of other HDACi [7]. Tumor inhibition and histone
acetylation were also noted in vivo in glioma, colon, and lung
tumor xenograft models [6].
Our current study seeks to extend these mechanistic
studies to acute leukemia cells and to clarify the speciﬁc role
of caspase-8 and the adaptor molecule Fas-associated death
domain (FADD) in the mechanism of apoptosis induced by
PCI-24781. Eﬀects on acetylation of histone H3 by PCI-
24781 were also examined in acute lymphocytic leukemia
(ALL) cells and in variants lacking caspase-8 or FADD, and
revealed a lower degree of histone H3 acetylation in the
latter lines. This surprising result highlights the importance
of these two components of the Fas receptor pathway in
conferring sensitivity to PCI-24781 in acute lymphocytic
leukemia cells.
2.MaterialandMethods
2.1. Cell Lines. Jurkat, I2.1 (FADD deﬁcient Jurkat cells)
and CEM human leukemia cell lines were acquired from
American Type Culture Collection (Manassas, VA). I9.2
(caspase-8 deﬁcient Jurkat cells) were provided by Dr.
Michael Andreeﬀ (The University of Texas M. D. Anderson
Cancer Center (UTMDACC), Houston, TX). All cells were
grown in a humidiﬁed incubator with 5% CO2 at 37
◦Ca n d
culturedinRPMI1640with10%(v/v)heat-inactivationfetal
bovine serum (Hyclone, Logan, UT), 2mM L-glutamine,
100U/mL penicillin, and 100μg/mL streptomycin (Sigma St.
Louis, MO).
2.2. Reagents. PCI-24781 was kindly provided by Phar-
macyclics Inc. (Sunnydale, CA). Trypsin-ethylenediam-
inetetraacetic acid (EDTA), propidium iodide (PI), N-
acetyl cysteine (NAC), Buthionine sulfoximine (BSO), and
Triton X-100 were purchased from Sigma (St. Louis,
MO). Dye for the detection of intracellular superoxide
(dihydroethidium [HEt]) was purchased from Molecular
Probes (Eugene, OR). Caspase-3 substrate, DEVD-amc,
was purchased from Biomol International, LP (Plymouth
Meeting, PA). The caspase inhibitors zVAD-fmk and IETD-
fmk were purchased from Calbiochem (San Diego, CA).
Antibodies were purchased for caspase-3 (Cell Signaling, San
Diego, CA), polyclonal anti-acetyl-histone H3 (Abcam, Inc.,
Cambridge, MA), and actin (Sigma). Annexin V-ﬂuorescein
isothiocyanate (Annexin V-FITC) was purchased from BD
Bioscience (Franklin Lakes, NJ). QVD-OPH was purchased
from MBL International (Woburn, MA)
2.3. Assessment of DNA Fragmentation. Apoptosis was
assessed by determining the percentage of subdiploid cells
using PI staining followed by ﬂow cytometric analysis as
previously described [8]. The cells were incubated for 24
hours, centrifuged, and resuspended in 500μLo fP Is o l u t i o n
(50μg/mL PI, 0.1% Triton X-100, and 0.1% sodium citrate
in PBS). Samples were assessed by ﬂow cytometry on the FL-
3 channel (FACSCalibur, Becton, Dickinson, Franklin Lakes
NJ). CellQuest software was used for the analysis of the data
(BD Bioscience, Franklin Lakes NJ).
2.4. Annexin V Staining. Phosphatidylserine was measured
by Annexin V-FITC staining according to the manufacturer’s
protocol. CEM cells were pretreated with 5μM QVD-OPH
(a pan caspase inhibitor) and treated with 0.5μM PCI-24781
for 30hours, washed twice in cold PBS, resuspended in
1X binding buﬀer (0.01M HEPES, pH 7.4; 0.14M NaCl;
2.5mM CaCl2), and incubated for 30 minutes in the dark
at room temperature with 5μL Annexin V-FITC and 10μL
of 50μg/mL PI. Samples were analyzed by ﬂow cytometry on
the FL-1 (for FITC) and FL-3 (for PI) channels and analyzed
using CellQuest software.
2.5. Detection of Intracellular Superoxide. The intracellular
superoxide level was measured using the cell-permeable HEt
dye as previously described [9]. Cells were centrifuged and
resuspended in 1mL of phosphate buﬀered saline (PBS)
containing 10μM HEt. The samples were incubated for 30
minutes in the dark at 37
◦C. Fluorescence intensity was
assessed by ﬂow cytometer on the FL-3 (for HEt) channel
and analyzed by CellQuest software.
2.6. Caspase-3-Like Activity Assays. Cells were centrifuged,
resuspended in 100μL PBS and lysed by freezing and
thawing. To each well, 50μL of lysate and 150μLo f5 0μM
DEVD-amc in DEVD buﬀer (10% sucrose, 0.001% IGEPAL,
0.1% CHAPS, 5mM HEPES, pH 7.25) were added in
duplicates on a 96-well plate. The release of ﬂuorescence
(amc) generated from the cleavage of DEVD-amc was
measured using a spectroﬂuorometer (SpectraMax Gemini
EM, Molecular Devices, Sunnyvale, CA) using an excitation
of 355nm and emission of 460nm.
2.7. Western Blotting. After treatment, Jurkat cells (5 ×
106) were resuspended in lysis buﬀer (1% Triton X-100,
150mM NaCl, 5mM EDTA, 20mM sodium phosphate,
pH 7.4). Aliquots of protein lysates (30μg) were loaded
on 12% sodium dodecyl sulfate- (SDS) polyacrylamide
gels, transferred to nitrocellulose membranes, and blocked
overnight at 4◦C with 5% nonfat dry milk in Tris-Buﬀered
Saline 0.05% Tween-20 (TBS-T). Membranes were probed
with 1 : 1000dilution of primary antibody in 5% milk in
TBS-T. The bound antibodies were detected using enhanced
chemiluminescence, ECL plus Western blotting detectionInternational Journal of Cell Biology 3
0
25
50
75
100
C
e
l
l
v
i
a
b
i
l
i
t
y
(
%
)
Control 0.01 0.10 .25 0.50 .75 1 5 10
Dose (μM)
∗
24h
36h
∗P-value <. 05
(a)
0
20
40
60
80
100
S
u
b
d
i
p
l
o
i
d
(
%
)
Control 0.01 0.10 .25 0.50 .75 1 5 10
Concentration (μM)
∗P-value <. 05
∗
24h treatment
(b)
Figure 1: The exposure of PCI-24781 increases cytotoxic eﬀects
of leukemic cells. Jurkat cells were treated with a range of PCI-
24781 doses (0.01μM–10μM), (a) incubated for 24 and 36 hours,
and the % cell viability was quantitated by trypan blue exclusion
using a Vi-Cell Coulter Counter, (b) incubated for 24 hours, dyed
with PI reagent, and analyzed by ﬂow cytometry to assess DNA
fragmentation. Error bars represent the means ± S.D. of three
independent experiments. ∗P < .05 compared to control.
system (Amerham Bioscience, UK limited, Little Chalfont
Buckinghamshire, England).
2.8. Statistical Analysis. For each condition, multiple exper-
iments were performed, and the results are presented as the
mean ± standard deviation (S.D). The diﬀerences between
twogroupconditionswereanalyzedusingindependent,two-
tailed t-tests (Microsoft Excel software, Redmond, WA).
3. Results
3.1. PCI-24781 Induces In Vitro Apoptotic Cell Death in
Leukemia Cells. Previous research indicated that PCI-24781
is cytotoxic in multiple solid tumor lines [6], however the
study of this drug in hematopoetic cells is limited to one
study conducted in Hodgkins lymphoma and non-Hodgkins
lymphoma cell lines [7]. To extend these mechanistic studies
to leukemia cells, the cytotoxic eﬀects of PCI-24781 were
investigated in an ALL cell line. Jurkat cells were treated with
a range of PCI-24781 doses (0.01μM–10μM), incubated for
24 hours and 36 hours, and percent viability was quantiﬁed
by trypan blue exclusion. As seen in Figure 1(a), there was a
signiﬁcant reduction in Jurkat cell viability beginning at the
0.25μM and 0.75μM dose of PCI-24781 after exposure for
24 or 36 hours, respectively, (P-value < .05).
Having identiﬁed doses at which PCI-24781 is cytotoxic
to ALL cells, the next step was to examine whether the
observed cell death was due to apoptosis. DNA fragmenta-
tion is a well-deﬁned characteristic of apoptosis and can be
quantiﬁed by measuring the increase in the percentage of
cellscontaining subdiploid amounts ofDNA bystaining cells
with PI. Jurkat cells were treated with a range of PCI-24781
doses(0.01μM–10μM),incubatedfor24hours,stainedwith
PI and assessed by ﬂow cytometry. Figure 1(b) shows that
a 24-hour exposure to PCI-24781 led to a dose-dependent
increase in DNA fragmentation beginning at the 0.1μMd o s e
(P-value < .05).
3.2. PCI-24781 Induced Apoptosis Is Caspase Dependent.
Having demonstrated that the cytotoxic eﬀects of PCI-
24781 in ALL cells involve DNA fragmentation, we next
investigated if a caspase-dependent apoptotic pathway was
activated. Jurkat cells were pretreated with 10μM zVAD-fmk
(a pan caspase inhibitor) for 30 minutes and then treated
with 5μM PCI-24781 for 24 hours, followed by PI staining
and ﬂow cytometry. As shown in Figure 2(a), the pan-
caspaseinhibitor alonehadnoeﬀectonDNAfragmentation.
However, apoptotic DNA fragmentation induced by PCI-
24781 was signiﬁcantly reduced when caspase activity was
blocked (P-value < .05).
Since caspase-3 activation induces apoptotic DNA frag-
mentation, this end point wasspeciﬁcallyexamined in Jurkat
cells in response to treatment with PCI-24781. Caspase-3-
like activity was measured by monitoring ﬂuorescence levels
generated from the hydrolysis of the DEVD-amc ﬂuorogenic
substrate. Jurkat cells were pretreated with zVAD-fmk for
30 minutes, and then treated with 5μM PCI-24781 for 16
hours. Figure 2(b) shows that 5μM PCI-24781 increased
caspase-3-like activity by 7-fold as compared with control.
In addition, pretreatment with the pan caspase inhibitor,
zVAD-fmk, successfully abrogated the increase of caspase-
3-like activity induced by 5μM PCI-24781 (P-value < .05).
Although caspase-3-like activity was higher with the 0.5μM
dose compared to 5μM PCI-24781, these results most likely
reﬂect that the higher dose (5μM) is peaking at an early
t i m ep o i n t .T h i si d e ai ss u p p o r t e db yFigure 3(d),i nw h i c h
a time course with 5μM revealed that maximum levels are
reachedat14hoursandbegintodeclineafterthistimepoint.
Analysis of later time points, after 16 hours, most likely will
further support this idea.
DEVD-amc has been criticized as a nonspeciﬁc substrate
for caspase-3,because it can detect caspase-3 and/or caspase-
7 activities. Caspase activation can also be measured by4 International Journal of Cell Biology
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Figure 2: The exposure of PCI-24781 induces caspase-dependentapoptosis in leukemic cells. (a) DNA fragmentation was assessed in Jurkat cells
treatedwith 5μM of PCI-24781 (PCI),with or without 30 minutes of zVAD-fmk pretreatment, incubated for24 hours,dyed with PI reagent,
and assessed on the ﬂow cytometer. (b) Jurkat cells were treated with 0.5μM and 5μM PCI-24781, with or without 30 minutes of zVAD-fmk
pretreatment, and incubated for 16 hours. Incubated cells were lysed and stained with DEVD-amc to measure caspase-3-like activity. The
release of amc was measured on a spectroﬂuorometer using an excitation of 355nm and an emission of 460nm. (c) In protein lysates from
cells treated with 5μM PCI-24781 for 16 hours, procaspase 3, cleaved caspase 3, and actin were measured by western blot. (d) CEM cells
were pretreated with 5μM QVD-OPH for 2hours and treated with 0.5μM PCI-24781 for 30 hours. Percentage cells positive with Annexin
V/PI staining was measured for both. Error bars ((a), (b), and (d)) represent the means ± S.D. of three independent experiments. ((a) and
(b)) ∗P < .05 relative to 5μM PCI-24781.
western blotting to visualize the cleavage of the large and
small subunits of the caspase. To investigate if PCI-24781
speciﬁcally results in caspase-3 activation, cleaved caspase-
3 was measured by western blot. The 19-kDa and 17-
kDa cleaved products were evident after treatment with
5μM PCI-24781, but there was no caspase-3 cleavage
when the drug was combined with zVAD-fmk pretreatment
(Figure 2(c)), verifying that caspase-3 activation is a conse-
quence of PCI-24781 treatment.
In order to further validate the results in Jurkat cells,
apoptosis was measured in a diﬀerent ALL cell line (CEM)
and by detection of a diﬀerent biochemical event that
occurs during apoptotic cell death. Annexin V binds to
phosphatidylserine displayed on the cell membrane, which
is required for eﬃcient disposal of the apoptotic cell. CEM
cells were pretreated with 5μM QVD-OPH and treated with
0.2μM PCI-24781 for 30 hours. Cells were stained with
Annexin V/PI and then analyzed by ﬂow cytometry. As
expected, in CEM cells, the percentage of Annexin V positive
cellsincreaseswithPCI-24781 treatmentanddecreaseswhen
caspase activation is inhibited in PCI-24781 treated cells
(Figure 2(d)).International Journal of Cell Biology 5
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Figure 3: PCI-24781 induces ROS generation in a caspase-dependent and time-dependent manner. (a) Jurkat cells were treated with 5μMo f
PCI-24781, incubated between 2 and 22 hours. Intracellular superoxide was measured at each time point using dihydroethidium (HEt) and
assessed by ﬂow cytometry. ∗P < .01 compared to control. (b) Jurkat cells were treated with a range of PCI-24781 doses (0.01μM–10μM),
and incubated 16 and 20 hours. The mean HEt ﬂuorescence at each dose was measured by ﬂow cytometry. ∗P < .05 compared to control.
(c) Jurkat cells were treated with 5μM PCI-24781, with or without zVAD-fmk pretreatment, and incubated for 24 hours, intracellular
superoxide levels were assessed using HEt. ∗P < .05. (d) Jurkat cells were treated with 5μM PCI-24781, incubated between 4 and 16 hours,
lysed and stained with DEVD-amc to assess caspase-3-like activity. Caspase-3 activity was measured in relative ﬂuorescence unit (RFU).
The release of amc was measured on a spectroﬂuorometer using an excitation of 355nm and an emission of 460nm. ∗P < .05 compared to
control. (e) Jurkat cells were pretreated with either inhibitor of caspase 8 (IETD-fmk) or a pan caspase inhibitor (zVAD-fmk) for 30 minutes.
After pretreatment, the samples were treated with 0.5 or 5μM PCI-24781 for 16 hours and dyed with PI reagent. DNA fragmentation (%
subdiploid) was assessed by ﬂow cytometer. (f) Jurkat and I9.2 cells were treated with or without 0.5μM PCI-24781 and incubated by 16
hours, dyed with PI reagent, and assessed on the ﬂow cytometer. ∗P < .05 relative to Jurkat 0.5μM PCI-24781. (a)–(f) Error bars represent
the means ± S.D. of three independent experiments. (g) Jurkat and I2.1 cells were treated with or without 0.5 or 5μM PCI-24781 and
incubated by 16 hours, dyed with PI reagent, and assessed on the ﬂow cytometer. ∗P < .05 relative to Jurkat cells treated with PCI-24781.
3.3. PCI-24781 Induces ROS Generation in a Caspase-
Dependent and Time-Dependent Manner. ROS have been
shown to induce apoptosis by the release of cytochrome c
from the mitochondria, which activates the caspase cascade.
Previous studies have shown that many cancer cells have
higher ROS levels compared to normal cells [10]. Therefore,
one therapeutic approach is to use ROS generating anti-
cancer agents that push intracellular ROS levels beyond a
critical threshold and induce apoptosis. Various anticancer
drugs like HDAC inhibitors have been shown to increase
intracellular ROS levels as a single agent [11]. Since we
observed caspase-3 activation in ALL cells treated with PCI-
24781, we sought to determine the role of ROS by measuring
intracellular superoxide levels. Jurkat cells were treated with
5μM of PCI-24781, incubated for various times spanning
2–22 hours, stained with dihydroethidium, and analyzed by
ﬂow cytometry. As shown in Figure 3(a), ROS increased in
a time-dependent manner beginning at 16 hours (P-value
< .01) and peaks at 20 hours. Figure 3(b) shows that ROS
also increases in a dose-dependent manner with PCI-24781
treatment, beginning at 0.5μM at both 16 hours and 20
hours time points (P-value < .05).
Thus, so far our ﬁndings indicate that PCI-24781
induces apoptosis, which can be linked to ROS generation
and/or caspase activation. The next step was to determine
if ROS generation precedes or follows caspase activation.
Superoxide levels were measured after exposure to 5μM
PCI-24781, with or without pretreatment of zVAD-fmk.
Figure 3(c) shows that when caspase activity is blocked, PCI-
24781 induced ROS generation is blunted (P-value = .03).
Therefore, caspase activation plays a role in the increase of
ROS levels seen with PCI-24781 treatment. Next, the kinetics
of caspase activation was examined. Jurkat cells treated with
5μM PCI-24781 were incubated between 4 and 16 hours,
and caspase-3-like activity was measured using DEVD-amc
as a substrate (Figure 3(d)). Since no ROS generation was
observed at 8 hours of exposure to the same dose of PCI-
24781 (data not shown), these results demonstrate that
c a s p a s ea c t i v a t i o no c c u r sﬁ r s t ,f o l l o w e db yR O Sg e n e r a t i o n .
A single study has examined the molecular mechanism
of apoptosis induction by PCI-24781 and reported that both
caspase-8 and -9 are cleaved and activated by the HDACi
in lymphoma lines. In order to more carefully examine
the role of caspase-8 in PCI-24781 induced cell death, we
used various peptide-based caspase inhibitors. Jurkat cells
were treated with 0.5μMa n d5 μM PCI-24781, with or
without pretreatment with either zVAD-fmk (a pan caspase
inhibitor) or an inhibitor of caspase-8 (IETD-fmk). After
16 hours the cells were stained with PI reagent and DNA
fragmentation was assessed by ﬂow cytometer as shown in
Figure 3(e). Results show no signiﬁcant diﬀerence between
0.5μMa n d5μM doses. Since 0.5μM represents a potentially
less toxic and more clinically relevant dose, we decided to
combine the lower dose (0.5μM) with the caspase inhibitors.International Journal of Cell Biology 7
Actin
Total H3
Actin
Ac H3
Control PCI NAC
PCI +
NAC
(a)
0
5
10
15
20
25
30
35
40
45
50
S
u
b
d
i
p
l
o
i
d
(
%
)
Control BSO PCI 0.5μM PCI 0.5μM
+B S O
Actin
Total H3
Actin
Ac H3
C
o
n
t
r
o
l
P
C
I
B
S
O
B
S
O
+
P
C
I
N
A
C
N
A
C
+
P
C
I
(b)
Actin
Total H3
Actin
Ac H3
C
o
n
t
r
o
l
I
E
T
D
-
f
m
k
z
V
A
D
-
f
m
k
P
C
I
P
C
I
+
I
E
T
D
-
f
m
k
P
C
I
+
z
V
A
D
-
f
m
k
(c)
Actin
Total H3
Actin
Ac H3
Jurkat
control
Jurkat
PCI
19.2
control
19.2
PCI
(d)
Actin
H3
Actin
Ac H3
Jurkat 12.1 (FADD deﬁcient)
PCI-24781
(nM)
0 250 500 0 250 500
(e)
Figure 4: PCI-24781 induces a caspase-dependent increase in both total and acetylated histone H3 protein expressions. Jurkat cells were treated
with0.5μM of PCI-24781, with or without pretreatment of (a) 24 mM NAC, (b) 1mM buthionine sulfoximine (BSO), (c) 50μM zVAD-fmk
or IETD-fmk, for 30 minutes. After 16 hours of incubation, samples were either harvested to determine DNA fragmentation by PI staining
or lysed for western blot. Acetylated histone H3, total histone H3, and actin were measured by western blot. (d) Jurkat and I9.2 cells were
treatedwithorwithout0.5μM PCI-24781 and incubated for 16 hours. Lysates were harvested and lysed. Acetylated histone H3, total histone
H3, and actin were measured by western blot. (e) Jurkat and I2.1 cells were treated with or without 0.25 or 0.5μM PCI-24781 and incubated
for 16 hours. Samples were harvested and lysed. Acetylated histone H3, total histone H3, and actin were measured by western blot. For
Figures 4(a)–4(d), results are representative of at least two independent experiments.8 International Journal of Cell Biology
DNA fragmentation by PCI-24781 was signiﬁcantly reduced
in the presence of IETD-fmk, suggesting that caspase-8 is
involved in the induction of apoptosis by PCI-24781. To
validate this result, I9.2 cells (a caspase-8 deﬁcient Jurkat
variant) [12] were treated with 0.5μM PCI-24781 for 16
hours. Figure 3(f) shows a signiﬁcant decrease of DNA
fragmentation in I9.2 cells treated with the HDACi as
compared with wildtype Jurkat cells, demonstrating again
the importance of caspase-8 in PCI-24781 induction of
apoptosis. Activation of caspase-8 requires participation of
an adaptor molecule which links the death receptor (Fas in
this case) with caspase activation. A second Jurkat cell vari-
ant, this one lacking FADD (I2.1), was used to further probe
the functionality of the Fas pathway [12]. Figure 3(g) indi-
cates that FADD deﬁciency reduces DNA fragmentation by
PCI-24781.
3.4. PCI-24781 Induces Total and Acetylated H3 Protein
Expression in a Caspase and FADD Dependent Manner. The
primary mechanism of action of HDAC inhibitors is to
prevent abnormal deacetylation of histones by antagonizing
HDAC enzymes. This mechanism has been hypothesized
to increase expression of tumor-suppressor genes. In order
to test whether PCI-24781 induced histone acetylation is
linked to the apoptotic pathway and generation of ROS,
Jurkat cells were treated with 0.5μM of PCI-24781, with or
without pretreatment of NAC (an antioxidant that works
by increasing levels of the most abundant intracellular
antioxidant,glutathione(GSH)),BSO(anagentthatdepletes
GSH) zVAD-fmk (the pan-caspase inhibitor), or IETD-
fmk (caspase-8 inhibitor), for 30 minutes. After 16 hours
of incubation, acetylated histone H3 (Ac H3) and total
histone H3 (total H3) were measured by western blot.
In addition DNA fragmentation was assessed for BSO
pretreatment samples. Results show that, as expected, PCI-
24781 exposure leads to an increase in acetylated histone H3
protein levels (Figures 4(a), 4(b) and 4(c)). Neither NAC nor
BSO changed the increase in Ac H3 (Figures 4(a) and 4(b)),
indicating that boosting or depleting GSH, respectively, has
no eﬀect on PCI-24781’s ability to hyperacetylate histone
H3. Consistent with this result, BSO depletion of GSH
did not promote further DNA fragmentation induction
by PCI-24781 when the two compounds were combined
(Figure 4(b)). In contrast, inhibition of caspase activation
with IETD-fmk or zVAD-fmk blocked the increase in Ac
H3 protein levels (Figure 4(c)), implicating caspases in
elevated levels of acetylated histone H3. To conﬁrm the
results obtained with the caspase-8 inhibitor, IETD-fmk, we
examined the eﬀects of PCI-24781 exposure on histone H3
acetylation in I9.2 cells. Our ﬁndings indicate that there
was less of an increase in Ac H3 protein levels in caspase-8
deﬁcient I9.2 cells as compared to Jurkat cells (Figure 4(d)).
Similar resultswereobtained using FADDdeﬁcientI2.1 cells,
supporting a role for FADD in the mechanism of PCI-
24781-mediated histone H3 acetylation (Figure 4(e)). The
diﬀerence between I2.1 and wildtype Jurkat cells was more
apparent at the lower (250nM) dose of PCI-24781, indicat-
ing that dose escalation could overcome the eﬀect of FADD
deﬁciency.
4. Discussion
The current study focuses on the cytotoxic eﬀects of a
hydroxamicacidHDACi,PCI-24781,inleukemiacells.Using
Jurkat cell variants that lack caspase-8 (I9.2) or FADD (I2.1),
we show that apoptosis induction and histone acetylation
by this HDACi are dependent upon these two proapoptotic
molecules. In particular, the eﬀects of FADD deﬁciency
are suggestive of a role for the extrinsic apoptotic pathway
triggered by Fas/Fas ligand interactions in these cells. Data
showing that inhibition of caspase activation by zVAD-fmk
or a lack of FADD or caspase-8 decreases the total and
acetylated protein levels of histone H3 induced by PCI-
24781 was unexpected and interesting (Figures 4(c)–4(e)).
Previous work in our laboratory has shown hyperacetylation
of histone H3 in caspase-8 deﬁcient cells when treated
with a diﬀerent HDACi, MS/SNDX-275, indicating that
PCI-24781 may be unique in this regard [13]. However, a
broader array of HDACi would need to be tested in order
to determine if caspase-8 dependent acetylation is a feature
exclusive to PCI-24781. Interestingly, this caspase-8 and
FADD dependent protection against DNA fragmentation
andhistonealterations,however,appearstobesurmountable
by increased doses of PCI-24781. As shown in Figure 3(e),
both the 0.5μMa n d5 μM doses of PCI-24781 induce
similar amounts of DNA fragmentation as assessed by the
percent subdiploid population. However, in comparing the
degree of protection conferred by FADD deﬁciency for
the two doses (Figure 3(g)), it is apparent that the higher
dose (5μM) of PCI-24781 is less protected than the lower
(0.5μM) dose. A similar pattern is observed when histone
H3 acetylation by PCI-24781 is examined in FADD deﬁcient
cells (Figure 4(d)), which further supports the relationship
between apoptosis induction and histone H3 acetylation.
The exact mechanism linking caspase-8 or FADD to histone
H3 acetylation is currently under investigation in our lab.
Both HDAC dependent and independent scenarios are being
considered. For HDAC dependent molecular explanations,
it has been reported that caspase cleavage of HDACs can
occur [14], resulting in their inactivation and histone H3
hyperacteylation. An HDAC-independent mechanism could
explain increased histone H3 acetylation and total histone
H3 levels if apoptotic DNA fragmentation (mediated by
caspases) was causing release of histones from DNA [15].
In this case, free histone H3 (some acetylated and some
unacetylated) would be detected in Triton soluble lysates to a
lesser degree when caspases are inhibited.
Our results also address a role for oxidative stress in
the mechanism of action of PCI-24781. Several structurally
diverse HDACi are reported to heighten intracellular levels
of superoxide and peroxide [11], and similar results were
obtained for PCI-24781 by others in lymphoma lines [7]a n d
by us in leukemia lines (Figures 3(a)–3(c)). This oxidative
stress appears caspase dependent since zVAD-fmk has a
statistically signiﬁcant, albeit modest eﬀect (Figure 3(c)).
However, the antioxidant, NAC, which eﬀectively blunts
ROS production by PCI-24781 (data not shown) did not
alter histone H3 acetylation by PCI-24781 (Figure 4(a)).
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supports the notion that the histone H3 eﬀects observed
in the caspase-8 deﬁcient and FADD deﬁcient results are
due to an HDAC dependent eﬀect rather than a generalized
apoptosis-mediated eﬀect. Given reports from other groups
that caspases can cleave speciﬁc HDAC family members
rendering them inactive [14], and our results indicating
that a pan-caspase inhibitor as well as a caspase-8 speciﬁc
inhibitor can reverse acetylation changes by PCI-24781
(Figure 4(b)), this possibility will be further explored. The
most widely cited mechanism of action for NAC’s antioxi-
dant eﬀects is by bolstering total cellular GSH levels. We used
BSO, a chemical inhibitor of the pathway critical for GSH
synthesis, to determine if depletion of GSH would promote
apoptosis and histone H3 acetylation by PCI-24781. It did
not (Figure 4(b)), and together with the lack of eﬀectofNAC
on PCI-induced hyperacetylation, indicate that modulating
GSH levels does not alter the drug’s acetylation eﬀects.
A role for death receptor induced apoptotic pathways
involving TRAIL and Fas has been investigated in the
mechanism of action of HDACi other than PCI-24781
such as trichostatin A [16], MS/SNDX-275 [17], valproic
acid [18], and vorinostat alone and in combination with
other agents such as proteasome inhibitors [12]. Caspase-
8 activation has been described in a handful of these
studies, however, components and regulators of the death
inducing signaling complex (DISC) which ultimately result
in caspase-8 activation have only been addressed in two
HDAC related papers. One study proposes that depsipeptide,
(also called FR901228) can upregulate FasL at the mRNA
level in osteosarcoma cells resulting in caspase-8 and -3
activation [19]. The same investigators also reported in a
subsequent paper that in Fas resistant osteosarcoma cells,
depsipeptide causes downregulation of c-FLIP [20]. Since c-
FLIP confers resistance to Fas-mediated apoptosis, lowering
levels of c-FLIP is able to overcome resistance and promote
caspase-8 activation. Whether these mechanisms will hold
true for PCI-24781’s eﬀects in leukemia cells remains to be
determined.
Despite the plethora of studies (including ours) citing
caspase activation as a conserved event during HDACi
induced cell death, numerous reports describe autophagic
cell death as a consequence of treatment with this class of
compounds.NostudyhasasyetlookedatPCI-24781’sability
to induce auutophagy. However, a recent paper examined
the caspase-8 and caspase-9 dependence of two hydroxamic
acid HDACi: LAQ824 and LBH589 [21]. These investigators
used a genetically tractable in vivo myc driven lymphoma
model in which death receptor signaling was compromised
due to overexpression of CrmA, a viral caspase-8 inhibitor,
or due to deﬁciency of TRAIL. Caspase-9 deﬁciency and
Apaf-1 deﬁciency were also incorporated into lymphoma
model. Interestingly, none of these approaches to block
caspase activation were able to prevent cell death by the
two HDACi in the long term with morphological features
of autophagy emerging. A caveat of these HDACi, though,
is that unlike PCI-24781, these two compounds are reported
to inhibit HDAC6, an HDAC family member which appears
to regulate aggresome formation and autophagy [22]. In
contrast,PCI-24781displaysthegreatestpotencyforHDAC1
with no apparent selectivity for HDAC6 as compared to the
remainder of the HDAC family.
Our work is the ﬁrst to implicate the adaptor protein
FADD speciﬁcally in the mechanism of action of an HDAC
inhibitor. Compellingly, in addition to its function in the
cytoplasm proximal to the Fas receptor, FADD is reported
to be localized to the nucleus of resting cells. Using an
internalization defective Fas mutant lymphoma cell line,
Fogeretal.foundthatFADDretainesitsabilitytotranslocate
from nuclei to cytoplasm and suggest that a caspase-
8 dependent feedback loop regulates FADD traﬃcking
[23]. This model raises interesting possibilities regarding
an endogenous role for nuclear FADD in transcriptional
complexes that routinely contain HDAC family members.
A molecular connection between HDACs and FADD oﬀers
insight into our novel observation that FADD deﬁciency is a
determinant of sensitivity to PCI-24781. Thus, extrapolating
ourﬁndingstootherHDACiandtoothercancermodelsmay
contribute to eﬀorts to maximize the therapeutic eﬃcacy of
this interesting and versatile class of agents.
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